🇪🇺 Nourianz in European Union

Nourianz (ISTRADEFYLLINE) regulatory status in European Union.

Marketing authorisation

EMA

  • Application: EMEA/H/C/005308
  • Marketing authorisation holder: Kyowa Kirin Holdings B.V.
  • Local brand name: Nouryant
  • Indication: Istradefylline is indicated in adults as an adjunctive treatment to levodopa based regimens in patients with Parkinson’s disease (PD) experiencing “OFF” time.
  • Status: rejected

Read official source →

Nourianz in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Neuroscience approved in European Union

Frequently asked questions

Is Nourianz approved in European Union?

Yes. EMA has authorised it.

Who is the marketing authorisation holder for Nourianz in European Union?

Kyowa Kirin Holdings B.V. holds the EU marketing authorisation.